ITRM20010136A0 - Composti utili per il trattamento di patologie che rispondono all'attivazione del recettore ppar-gamma. - Google Patents

Composti utili per il trattamento di patologie che rispondono all'attivazione del recettore ppar-gamma.

Info

Publication number
ITRM20010136A0
ITRM20010136A0 IT2001RM000136A ITRM20010136A ITRM20010136A0 IT RM20010136 A0 ITRM20010136 A0 IT RM20010136A0 IT 2001RM000136 A IT2001RM000136 A IT 2001RM000136A IT RM20010136 A ITRM20010136 A IT RM20010136A IT RM20010136 A0 ITRM20010136 A0 IT RM20010136A0
Authority
IT
Italy
Prior art keywords
ppar
respond
diseases
activation
treatment
Prior art date
Application number
IT2001RM000136A
Other languages
English (en)
Inventor
Claudio Pisano
Teresa Riccioni
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority to IT2001RM000136A priority Critical patent/ITRM20010136A1/it
Publication of ITRM20010136A0 publication Critical patent/ITRM20010136A0/it
Priority to KR1020037012030A priority patent/KR100851678B1/ko
Priority to PL02369295A priority patent/PL369295A1/xx
Priority to EP02717031A priority patent/EP1368025B1/en
Priority to JP2002572999A priority patent/JP4276842B2/ja
Priority to HK05107335.4A priority patent/HK1075006B/xx
Priority to HU0303518A priority patent/HUP0303518A3/hu
Priority to AT02717031T priority patent/ATE308984T1/de
Priority to MXPA03008317A priority patent/MXPA03008317A/es
Priority to SI200230214T priority patent/SI1368025T1/sl
Priority to CZ20032523A priority patent/CZ20032523A3/cs
Priority to ES02717031T priority patent/ES2249568T3/es
Priority to DK02717031T priority patent/DK1368025T3/da
Priority to US10/471,786 priority patent/US6897235B2/en
Priority to AU2002247951A priority patent/AU2002247951B2/en
Priority to PCT/IT2002/000127 priority patent/WO2002074291A2/en
Priority to BR0208157-1A priority patent/BR0208157A/pt
Priority to CA2440979A priority patent/CA2440979C/en
Priority to CNB028081382A priority patent/CN1286456C/zh
Priority to DE60207215T priority patent/DE60207215T2/de
Priority to SK1275-2003A priority patent/SK12752003A3/sk
Priority to CNB2006100057819A priority patent/CN100462073C/zh
Publication of ITRM20010136A1 publication Critical patent/ITRM20010136A1/it
Priority to US10/889,030 priority patent/US20040242675A1/en
Priority to US10/889,029 priority patent/US7276533B2/en
Priority to US10/965,740 priority patent/US20050131060A1/en
Priority to HK07101784.1A priority patent/HK1096850B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
IT2001RM000136A 2001-03-15 2001-03-16 Composti utili per il trattamento di patologie che rispondono all'attivazione del recettore ppar-gamma. ITRM20010136A1 (it)

Priority Applications (26)

Application Number Priority Date Filing Date Title
IT2001RM000136A ITRM20010136A1 (it) 2001-03-16 2001-03-16 Composti utili per il trattamento di patologie che rispondono all'attivazione del recettore ppar-gamma.
CNB2006100057819A CN100462073C (zh) 2001-03-16 2002-03-01 用于治疗对PPAR-γ受体的活化有响应的病变的组合物
DK02717031T DK1368025T3 (da) 2001-03-16 2002-03-01 Præparater, der er nyttige til behandling af patologier, som udviser respons på aktiveringen af PPAR-gammareceptor
AU2002247951A AU2002247951B2 (en) 2001-03-16 2002-03-01 Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor
EP02717031A EP1368025B1 (en) 2001-03-16 2002-03-01 Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor
JP2002572999A JP4276842B2 (ja) 2001-03-16 2002-03-01 Ｐｐａｒ−ガンマ受容体の活性化に応答する症状の治療に有用な組成物
HK05107335.4A HK1075006B (en) 2001-03-16 2002-03-01 Use of spirolaxine for the preparation of a medicament treating type 2 insulin-resistant diabetes mellitus
HU0303518A HUP0303518A3 (en) 2001-03-16 2002-03-01 Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor
AT02717031T ATE308984T1 (de) 2001-03-16 2002-03-01 Arzneiformen zur behandlung von krankheiten, die auf aktivierung des ppar-gamma-rezeptors ansprechen
MXPA03008317A MXPA03008317A (es) 2001-03-16 2002-03-01 Composiciones utiles para el tratamiento de patologias que responden a la activavion del receptor ppar-gama.
SI200230214T SI1368025T1 (sl) 2001-03-16 2002-03-01 Zmesi, ki so uporabne za zdravljenje patologij odzivanja na aktiviranje PPAR-gama receptorja
CZ20032523A CZ20032523A3 (cs) 2001-03-16 2002-03-01 Přípravek vhodný k léčbě patologické reakce na aktivaci PPAR gamma receptoru
ES02717031T ES2249568T3 (es) 2001-03-16 2002-03-01 Composiciones utiles para el tratamiento de patologias que responden a la activacion del receptor ppar-gamma.
KR1020037012030A KR100851678B1 (ko) 2001-03-16 2002-03-01 Ｐｐａｒ-감마 수용체의 활성화에 반응하는 질병의 치료에유용한 조성물
US10/471,786 US6897235B2 (en) 2001-03-15 2002-03-01 Compositions useful for the treatment of pathologies responding to the activation of PPAR-γ receptor
PL02369295A PL369295A1 (en) 2001-03-16 2002-03-01 Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor
PCT/IT2002/000127 WO2002074291A2 (en) 2001-03-16 2002-03-01 Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor
BR0208157-1A BR0208157A (pt) 2001-03-16 2002-03-01 Composições úteis para o tratamento de patologias respondendo à ativação de receptor ppar-gama
CA2440979A CA2440979C (en) 2001-03-16 2002-03-01 Spirolaximes for use in the treatment of pathologies that respond to ppar-.gamma. receptor activation
CNB028081382A CN1286456C (zh) 2001-03-16 2002-03-01 螺莱素用于制备治疗2型抗胰岛素性糖尿病的药物的应用
DE60207215T DE60207215T2 (de) 2001-03-16 2002-03-01 Arzneiformen zur behandlung von krankheiten, die auf aktivierung des ppar-gamma-rezeptors ansprechen
SK1275-2003A SK12752003A3 (sk) 2001-03-16 2002-03-01 Prípravky užitočné na liečbu patológií odpovedajúce na aktiváciu PPAR-gamma receptora
US10/889,029 US7276533B2 (en) 2001-03-15 2004-07-13 Compositions useful for the treatment of pathologies responding to the activation of PPAR-gamma receptor
US10/889,030 US20040242675A1 (en) 2001-03-15 2004-07-13 Compositions useful for the treatment of pathologies responding to the activation of PPAR-gamma receptor
US10/965,740 US20050131060A1 (en) 2001-03-16 2004-10-18 Compositions useful for the treatment of pathologies responding to the activation of PPAR-gamma receptor
HK07101784.1A HK1096850B (en) 2001-03-16 2007-02-15 Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001RM000136A ITRM20010136A1 (it) 2001-03-16 2001-03-16 Composti utili per il trattamento di patologie che rispondono all'attivazione del recettore ppar-gamma.

Publications (2)

Publication Number Publication Date
ITRM20010136A0 true ITRM20010136A0 (it) 2001-03-16
ITRM20010136A1 ITRM20010136A1 (it) 2002-09-16

Family

ID=11455333

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2001RM000136A ITRM20010136A1 (it) 2001-03-15 2001-03-16 Composti utili per il trattamento di patologie che rispondono all'attivazione del recettore ppar-gamma.

Country Status (19)

Country Link
US (4) US6897235B2 (it)
EP (1) EP1368025B1 (it)
JP (1) JP4276842B2 (it)
KR (1) KR100851678B1 (it)
CN (2) CN100462073C (it)
AT (1) ATE308984T1 (it)
AU (1) AU2002247951B2 (it)
BR (1) BR0208157A (it)
CA (1) CA2440979C (it)
CZ (1) CZ20032523A3 (it)
DE (1) DE60207215T2 (it)
DK (1) DK1368025T3 (it)
ES (1) ES2249568T3 (it)
HU (1) HUP0303518A3 (it)
IT (1) ITRM20010136A1 (it)
MX (1) MXPA03008317A (it)
PL (1) PL369295A1 (it)
SK (1) SK12752003A3 (it)
WO (1) WO2002074291A2 (it)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US20070082947A1 (en) * 2003-05-14 2007-04-12 D Orazio Daniel Use of phthalide derivatives for the treatment and prevention of diabetes mellitus
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
KR20090066289A (ko) 2006-09-08 2009-06-23 로드아일랜드하스피틀 알코올 유발성 뇌 질환의 치료, 예방 및 역행

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07285862A (ja) 1994-04-21 1995-10-31 Kokka Iyaku Kanrikyoku Shisen Kokinso Kogyo Kenkyusho 脂質低下剤
JPH107557A (ja) 1996-06-17 1998-01-13 Banyu Pharmaceut Co Ltd 抗腫瘍性物質スピロラキシン
US6440961B1 (en) * 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
IT1317001B1 (it) * 2000-03-13 2003-05-26 Sigma Tau Ind Farmaceuti Uso della spirolaxina per il trattamento di patologie associate ad unaalterata angiogenesi.

Also Published As

Publication number Publication date
HK1096850A1 (zh) 2007-06-15
SK12752003A3 (sk) 2004-01-08
US20040241228A1 (en) 2004-12-02
HK1075006A1 (en) 2005-12-02
DK1368025T3 (da) 2005-12-19
JP4276842B2 (ja) 2009-06-10
EP1368025B1 (en) 2005-11-09
CA2440979C (en) 2010-07-13
DE60207215D1 (de) 2005-12-15
CN1839823A (zh) 2006-10-04
US20040092540A1 (en) 2004-05-13
US7276533B2 (en) 2007-10-02
DE60207215T2 (de) 2006-07-20
CN100462073C (zh) 2009-02-18
KR100851678B1 (ko) 2008-08-13
US6897235B2 (en) 2005-05-24
CN1610545A (zh) 2005-04-27
BR0208157A (pt) 2004-03-02
WO2002074291A2 (en) 2002-09-26
US20050131060A1 (en) 2005-06-16
CA2440979A1 (en) 2002-09-26
US20040242675A1 (en) 2004-12-02
HUP0303518A2 (hu) 2004-03-01
JP2004523578A (ja) 2004-08-05
CZ20032523A3 (cs) 2004-05-12
CN1286456C (zh) 2006-11-29
AU2002247951B2 (en) 2007-03-01
HUP0303518A3 (en) 2005-12-28
EP1368025A2 (en) 2003-12-10
ES2249568T3 (es) 2006-04-01
WO2002074291A3 (en) 2003-03-13
KR20040025905A (ko) 2004-03-26
ITRM20010136A1 (it) 2002-09-16
MXPA03008317A (es) 2003-12-11
ATE308984T1 (de) 2005-11-15
PL369295A1 (en) 2005-04-18

Similar Documents

Publication Publication Date Title
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
SI1425277T1 (sl) Seäśninske spojine, aktivne kot vaniloidni receptorski antagonisti za zdravljenje boleäśine
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
BR0212250B1 (pt) produto de cuidado pessoal.
DK1562932T3 (da) 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter
DE60236218D1 (de) CCR5 Antagonisten verwendbar für die Behandlung von Aids
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
NO20033803D0 (no) Karbamat for behandling av bevegelseslidelser
ITMI20031311A0 (it) Formulazioni per il trattamento di disturbi artrosici
ITMI20020773A1 (it) Farmaci per il trattamento dell'artrite
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
NO20033804L (no) Karbamatforbindelser for behandling av smerte
ITMI20010077A0 (it) Procedimento per la produzione dell'imipenem
ITGE20020050A0 (it) Procedimento per il trattamento di filati mediante agugliatura.
EP1389456A4 (en) COSMETIC SURGERY PROCESS
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
ATE345818T1 (de) S-methyl-dihydro-ziprasidone zur behandlung von psychiatrischen störungen.
EP1295864A4 (en) PROCESS FOR THE PREPARATION OF 1,5-DIAMINONAPHTHALINES
HUP0303518A3 (en) Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor
IS6020A (is) S-nítrósóþíól til meðferðar við blóðrásartruflunum
ITMI20011284A0 (it) Composizione farmaceutica per il trattamento dell'iperfosfatemia
EA200200750A1 (ru) Новое терапевтическое применение еноксапарина
NO20053562L (no) Nye aminobenzofenonforbindelser